Sanofi, Regeneron PCSK9 trial uses new recruitment tool

Sanofi, Regeneron and the American College of Cardiology announced Thursday that they were taking a team approach to an investigational monoclonal antibody that will target PCSK9, which is associated with LDL levels. The trio will investigate alirocumab, which Sanofi and Regeneron are developing.